One of the most hated drug companies on Wall Street is facing...


Senator Claire McCaskill has sent a letter to Mallinckrodt Pharmaceuticals, asking the company for details about the pricing of its pain medication, Ofirmev. Ofirmev can be used as a safer alternative to opioids, and Mallinckrodt acquired the drug in 2014 when it purchased Cadence Pharmaceuticals for $1.4 billion.



from Biotech News